Renal Cell Carcinoma Treatment

SEP 10, 2026 · JOURNAL ARTICLE

Prediction of Acute Kidney Injury in Oncology: From Clinical Risk Scores to AI-Enabled Precision Onco-Nephrology

Cancers

A narrative review synthesizing evidence on AKI prediction in oncology that identifies gaps, methodological limitations, and priorities for clinical translation rather than reporting a primary empirical finding.

SEP 10, 2026 · JOURNAL ARTICLE

A phase II study assessing the feasibility and clinical efficacy of adaptive immunotherapy combination with VEGFR-TKI in patients with advanced renal cell carcinoma

Future Oncology

Phase II feasibility and safety study of an adaptive immunotherapy-TKI combination in advanced RCC; early-stage design testing a novel treatment approach with surrogate endpoints rather than hard clinical outcomes.

SEP 9, 2026 · JOURNAL ARTICLE

Prognostic and immunobiological relevance of an onco-immune signature in clear cell renal cell carcinoma

Clinical and Experimental Medicine

A retrospective derivation and validation study identifying a three-gene prognostic score in ccRCC with independent association to overall survival; sound design but limited by retrospective nature, single-center derivation cohort, and lack of prospective validation.

SEP 9, 2026 · JOURNAL ARTICLE

Case Report: No radiographic evidence of disease for 45 months in a patient with recurrent clear cell renal cell carcinoma treated with third-line combination therapy utilizing toripalimab and axitinib

Frontiers in Immunology

A single case report with sustained disease response offers an anecdotal observation but lacks the controlled design, comparator, or sample size needed to establish efficacy; the authors explicitly acknowledge limited evidence requiring validation.

SEP 8, 2026 · JOURNAL ARTICLE

Surgical decision–making in borderline resectable pancreatic cancer in the era of neoadjuvant therapy: from response assessment to individualized operative strategy

Frontiers in Surgery

This is a structured narrative review synthesizing evidence and international guidelines on surgical management of borderline resectable pancreatic cancer in the neoadjuvant therapy era, offering a practical decision-making framework rather than reporting original trial data.

SEP 7, 2026 · JOURNAL ARTICLE

Immune checkpoint inhibitor usage in a sequential kidney transplant stage IV squamous cell carcinoma patient

Journal of Onco-nephrology

Single case report with no control group, describing tolerance of anti-PD-1 therapy in an unusual patient population; raises a question about feasibility rather than establishing efficacy or safety.

SEP 5, 2026 · JOURNAL ARTICLE

Real-world outcomes and immune-related adverse events with PD-1/ PD-L1 inhibitors in metastatic renal cell carcinoma: A prospective observational study

Asian Journal of Oncology

Single-center prospective observational study with modest sample size (n=31) and surrogate endpoint (ORR at 3 months); demonstrates feasibility in a LMIC setting but lacks a comparator and control group, and requires confirmation in larger studies.

AUG 18, 2026 · JOURNAL ARTICLE

Cost-effectiveness analysis of disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing advanced urothelial cancer

Human Vaccines & Immunotherapeutics

A modeled cost-effectiveness analysis from a single healthcare system showing the intervention meets the threshold, but dependent on assumptions about treatment duration and subsequent costs that proved sensitive in scenario testing.